Sartorius Stedim reported solid FY20 numbers with 34.6%/56.7% growth in revenue/order book, respectively. Growth was largely attributable to bioprocessing (+34.4%/+56.4% revenue/order growth). EBITDA came in at €604.7m (+43.5%), with the associated margin at 31.7%. For FY21, the top-line growth/EBITDA margin is expected at 20-26%/32% respectively. The company also raised its mid-term outlook – FY25 revenue of €4bn (vs €2.8bn previously) and an EBITDA margin of 33% (vs 30% earlier). We will upgra ....
11 Feb 2021
Strong FY20 drives mid-term guidance upgrade
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong FY20 drives mid-term guidance upgrade
- Published:
11 Feb 2021 -
Author:
Virendra Chauhan -
Pages:
3
Sartorius Stedim reported solid FY20 numbers with 34.6%/56.7% growth in revenue/order book, respectively. Growth was largely attributable to bioprocessing (+34.4%/+56.4% revenue/order growth). EBITDA came in at €604.7m (+43.5%), with the associated margin at 31.7%. For FY21, the top-line growth/EBITDA margin is expected at 20-26%/32% respectively. The company also raised its mid-term outlook – FY25 revenue of €4bn (vs €2.8bn previously) and an EBITDA margin of 33% (vs 30% earlier). We will upgra ....